Focus Diagnostics competitors

Key experiences in leading mergers and acquisitions, working with financial institutions and markets, driving exceptional growth in revenue and profit, developing organizations, managing organizational performance, and planning strategic growth. Specialties: Mergers and acquisitions, General Management, Marketing, Sales, Quality Systems.

Chief Executive Officer and member of the board of XOMA (NASDAQ: XOMA). Joined XOMA in 2009 and was appointed to the CEO role in late 2016. In early 2017, Mr. Neal led XOMA through a dramatic strategic pivot taking the company from a traditional R&D heavy biotech company and transforming it to a successful royalty monetization and aggregation company. In the years prior to becoming CEO of XOMA, he was instrumental in leading the company’s licensing and business development activities focused on maximizing the value of XOMA’s foundational antibody IP and knowhow. In addition to his role at XOMA, Mr. Neal currently serves as a Director at Leading Biosciences, a clinical stage biotech company based in Carlsbad, CA. Mr. Neal has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Prior to XOMA, Mr. Neal was Acting Chief Executive Officer of Entelos Inc., a leading bio-simulation company that acquired Iconix Biosciences, a privately held company where Mr. Neal was Chief Executive Officer. At Iconix, Mr. Neal established multi-year collaborations with Bristol-Myers Squibb, Abbott Labs (now AbbVie), Eli Lilly and the U.S. Food and Drug Administration. From 1999-2002, he was Executive Vice President of Incyte Genomics, leading global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis, GSK and others. Earlier in his career, he was an executive with Monsanto Company in positions of increasing responsibility. Mr. Neal earned his B.S. in Biology and his M.S. in Genetics and Plant Breeding from the University of Manitoba, Canada, and holds an MBA degree from Washington University in St. Louis, MO.

Skip Wagner is a President and Chief Executive Officer at BioReliance and is based in College Station, Texas.

Bill Mosteller E. is a Chief Executive Officer at Diagnostic Laboratory of Oklahoma and is based in United States.

Mark Leuchtenberger is a Board Member at Melinta Therapeutics Inc, Co-Founder at Alvos Therapeutics Inc, and Executive Chairman at Aleta Biotherapeutics and is based in Boston, Massachusetts. He has experience at Bain & Company and has worked as Board Member at Targanta Therapeutics; Chairman at XENETIC BIOSCIENCES, INC.; and Senior Officer at Biogen Idec. Mark works or has worked as BOARD MEMBER at Wake Forest University - WFU and Chairman at MassBio. He studied at Wake Forest University - WFU; Wake Forest University, Yale School of Management; and Yale School of Management between 1985 and 1987.

Tony Balda has dedicated over 15 years to the healthcare and med-tech industry. He has been Chief Executive Officer of Medicomp since 2014. Tony is responsible for day-to-day business operations, the organization’s strategic advancement in the marketplace, as well as the growth and development. Prior to Medicomp, Tony was VP of Marketing and Strategy for the Telemedicine division of United Therapeutics. Tony earned his MBA from Wharton and his BA in applied Economics and management from Cornell University.